Annual reportSep 2026
Sep 2026 · Shareholders meeting 13 Aug - AGM on 7 September 2026; annual report filed; ₹10 crore RPT with Hetvi Lifesciences proposed.
Source: Nse
Sunrest Lifescience Ltd. (SUNREST)
SME CapPharma stocks · SME cap · NSE
Sunrest Lifescience Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result01 Jun, 07:58 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
64BullishSMA20 -4.9% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 42
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SUNRESTD candles · FIT view+5.9%Latest close ₹37.65 on 2026-10-16
Bar
+3.7%
RSI
51
MACD hist
-0.19
52W pos
33%
2026-10-16O ₹36.30H ₹40.40L ₹36.30C ₹37.65Vol 17,600 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SUNRESTNifty PharmaNifty 500
- SUNREST
- +7.6%
- Nifty 500
- -4.2%
- Nifty Pharma
- -1.0%
- Vs Nifty 500
- +11.7 pp
Chart stats
16 Oct 2026- From 52W high
- -38.3%
- 52W range position
- 26%
- ATR (14)
- 6.1%
- Volume vs 20D
- 2.93x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹33 - ₹40.4
₹61
₹29.6 - ₹61
₹2.3
Latest completed session
20-session average
77.8% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED68
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish64
Price trend and sector-relative-strength timing.
Valuation
Legacy model+91.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence63
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹36.8 Cr | NDF | +8.3% |
| EBITDA | ₹6.8 Cr | NDF | +175.5% |
| Operating margin | 18.3% | NDF | +1113 bps |
| PAT | ₹6.6 Cr | NDF | +895.5% |
| PAT margin | 17.8% | NDF | +1590 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 5.47
- P/B
- 0.75
- EV/EBITDA
- 2.86
- Market Cap
- 15.20Cr
Profitability
- ROE
- 15.20%
- ROCE
- 23.20%
- ROA
- 11.20%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 111.40%
- EPS 5Y
- 296.04%
- Revenue 3Y
- 111.40%
- EPS 3Y
- 296.04%
Balance Sheet
- Debt/Equity
- 0.85
- Interest Coverage
- 7.19×
- Altman Z
- 2.06
- Book Value
- 47.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- -0.05 Cr
- EPS TTM
- 9.60
Shareholding
- Promoter Hold
- 53.50%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 24%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 36.8+8.3% vs prev
Net Profit
₹ CrLatest: 6.6+895.5% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 51. Wait for confirmation.
- SMA20 falling (~5.1% over last month) — short-term momentum negative.
- RSI(14) at 51 — rising, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 30% off 52W high · 27% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 68 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 68 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation30/30
Growth24/25
Quality12/20
Balance Sheet7/15
Cash Flow0/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
68
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
68/100 · legacy band UNDERVALUED
Positive drivers
- Fair-value margin of safety is positive at 91.4%.
- Valuation contributes 30/30 to the score.
- Growth contributes 24/25 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
- Balance sheet is weaker at 7/15; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
5.5
PB
0.8
EV/EBITDA
2.9
ROE
15.2%
ROCE
23.2%
FCF Yield
—
Debt/Equity
0.8
MoS
+91.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
68
Previous: 68
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+91.4%
Previous: +91.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
68
68
68
68
68
68
68
68
68
68
68
68
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹101.4
+63.5% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹432
+91.4% MoS
PEG
0.02
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MONOPHARMA
SME
Mono Pharmacare Ltd.
Pharmaceuticals
match 164
18
21.6
2.3%
-408%
OVERVALUED
JFLLIFE
SME
JFL Life Sciences Ltd.
Pharmaceuticals
match 155
69
5.0
15.0%
+89%
UNDERVALUED
QUESTLAB
SME
Quest Laboratories Ltd.
Pharmaceuticals
match 150
70
11.3
16.6%
+78%
UNDERVALUED
ZENITHDRUG
SME
Zenith Drugs Ltd.
Pharmaceuticals
match 149
75
6.9
26.3%
+84%
DEEP VALUE
ARISTO
SME
Aristo Bio-Tech and Lifescience Ltd.
Pharmaceuticals
match 149
77
8.5
17.6%
+81%
DEEP VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Sunrest Lifescience Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
63Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 38th percentile of the scored universe and 27th percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
38th percentile
overall median 67 · Pharma: 27th pctile, median 70 · SME: 45th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
90
strong · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸ROCE is 28.6%.
Trust risks
- ▸Operating cash flow is negative at ₹0 Cr.
- ▸Only 1 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Sunrest Lifescience Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.